Skip to main content
SpringerLink
Log in

Viral Hepatitis

  • Chapter
  • First Online:
Viral Infections in Children, Volume II

  • 541 Accesses

Abstract

Hepatitis is a general term, which refers to the inflammation of the liver. Hepatitis occurs as a result of infection with various pathogens, exposure to alcohol, medications, chemicals, toxins, as well as immune disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Koff RS, Hepatitis A. Lancet. 1998;351:1643–9.

    Article  CAS  PubMed  Google Scholar 

  2. Brown EA, Stapleton JT. Hepatitis A virus. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, editors. Manual of clinical microbiology, Vol. 2. 8th ed. Washington, DC: ASM Press; 2003. p. 1452.

    Google Scholar 

  3. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunisation. MMWR. 2006;55(RR-7):1–23.

    Google Scholar 

  4. Curry MP, Chopra S. Acute viral hepatitis. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett’s: principles and practice of infectious diseases, Vol. 1. 6th ed. Philadelphia: Elsevier; 2005. p. 1426.

    Google Scholar 

  5. Mohd Hanafiah K, Jacobsen KH, Wiersma ST. Challenges to mapping the health risk of hepatitis A virus infection. Int J Health Geogr. 2011;10:57.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Cuthbert JA. Hepatitis A: old and new. Clin Microbiol Rev. 2001;14:38–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Bower WA, Nainan OV, Han X, Margolis HS. Duration of viremia in hepatitis A virus infection. J Infect Dis. 2000;182:12–7.

    Article  CAS  PubMed  Google Scholar 

  8. Jacobsen KH. Hepatitis A virus in West Africa: is an epidemiological transition beginning? Niger Med J. 2014;55(4):279–84.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55.

    Article  PubMed  Google Scholar 

  10. Maynard JE. Hepatitis B: global importance and need for control. Vaccine. 1990;8(Suppl):S18–20.

    Article  PubMed  Google Scholar 

  11. Norder H, Hammas B, Lee SD, Bile K, Courouce AM, Mushahwar IK, et al. Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen. J Gen Virol. 1993;74(7):1341–8.

    Article  CAS  PubMed  Google Scholar 

  12. Kramvis A, Kew MC. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepat. 2005;12(5):456–64.

    Article  CAS  PubMed  Google Scholar 

  13. Kew MC, Reis P, Macnab GM. The witch doctor and tribal scarification of the skin and the hepatitis B antigen. S Afr Med J. 1973;47(50):2419–20.

    CAS  PubMed  Google Scholar 

  14. Vardas E, Mathai M, Blaauw D, McAnerney J, Coppin A, Sim J. Preimmunization epidemiology of hepatitis B virus infection in South African children. J Med Virol. 1999;58(2):111–5.

    Article  CAS  PubMed  Google Scholar 

  15. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97–107.

    Article  CAS  PubMed  Google Scholar 

  16. Burnett RJ, Kramvis A, Dochez C, Meheus A. An update after 16 years of hepatitis B vaccination in South Africa. Vaccine. 2012;30(Suppl 3):C45–51.

    Article  PubMed  Google Scholar 

  17. Burnett RJ, Ngobeni JM, François G, et al. Increased exposure to hepatitis B virus infection in HIV-positive South African antenatal women. Int J STD AIDS. 2007;18(3):152–6.

    Article  CAS  PubMed  Google Scholar 

  18. Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis. 1994;170(6):1418–23.

    Article  CAS  PubMed  Google Scholar 

  19. Edmunds WJ, Medley GF, Nokes DJ, O’Callaghan CJ, Whittle HC, Hall AJ. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect. 1996;117(2):313–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat. 2003;10(4):294–7.

    Article  PubMed  Google Scholar 

  21. Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009;16(2):94–103.

    Article  PubMed  Google Scholar 

  22. Jones CE, Naidoo S, De Beer C, Esser M, Kampmann B, Hesseling AC. Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants. JAMA. 2011;305(6):576–84.

    Article  CAS  PubMed  Google Scholar 

  23. Petrova M, Kamburov V. Breastfeeding and chronic HBV infection: clinical and social implications. World J Gastroenterol. 2010;16(40):5042–6.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Schaefer S. Hepatitis B virus: significance of genotypes. J Viral Hepat. 2005;12(2):111–24.

    Article  CAS  PubMed  Google Scholar 

  25. De Schryver AA, Van Hooste W, et al. Managing risk of hepatitis B after sharps injuries. BMJ. 2015;351:h5568.

    Article  PubMed  Google Scholar 

  26. Beath SV, Boxall EH, Watson RM, Tarlow MJ, Kelly D. Fulminant hepatitis B in infants born to anti-HBe hepatitis B carrier mothers. BMJ. 1992;304:1169–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Hawkins AE, Gilson RJC, Beath SV, Boxall EH, Kelly DA, Tedder RS, Weller IVD. Novel application of a point mutation assay: evidence for transmission of hepatitis B virus with precore mutations and their detection in infants with fulminant hepatitis B. J Med Virol. 1994;44:13–21.

    Article  CAS  PubMed  Google Scholar 

  28. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–85.

    Article  Google Scholar 

  29. Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83.

    Article  PubMed  Google Scholar 

  30. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49(5 Suppl):S45–55.

    Article  CAS  PubMed  Google Scholar 

  31. Chen CJ, Iloeje UH, Yang H. Long-term outcomes in Hepatitis B: the REVEAL-HBV study. Clin Liver Dis. 2007;11:797–816.

    Article  PubMed  Google Scholar 

  32. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130(3):678–86.

    Google Scholar 

  33. Yang H, Lu S, Liaw Y, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168–74.

    Article  CAS  PubMed  Google Scholar 

  34. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35–50.

    Article  PubMed  Google Scholar 

  35. Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol. 2005;79(15):9369–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006;43(2 Suppl 1):S173–81.

    Article  CAS  PubMed  Google Scholar 

  37. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis. 2003;23(1):47–58.

    Article  PubMed  Google Scholar 

  38. Giovanna F, Bortolotti F, Francesco D. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335–52.

    Article  CAS  Google Scholar 

  39. Guillevin L, Lhote F, Cohen P, Sauvaget F, Jarrousse B, Lortholary O, et al. Polyarteritis nodosa related to hepatitis B virus: a prospective study with long-term observation of 41 patients. Medicine. 1995;74(5):238–53.

    Article  CAS  PubMed  Google Scholar 

  40. Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, Moyer LA, Bell BP, Alter MJ. A comprehensive immunisations strategy to eliminate hepatitis B virus transmission in the United States. Part 1: immunisation of infants, children and adolescents. MMWR. 2005;54(RR-16):1–3.

    PubMed  Google Scholar 

  41. Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ. HIV-HBV co-infection-a global challenge. N Engl J Med. 2012;366:1749.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Matthews PC, Geretti AM, Goulder PJ, Klenerman P. Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa. J Clin Virol. 2014;61:20.

    Article  PubMed  Google Scholar 

  43. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis. 2007;7(6):402–9.

    Article  PubMed  Google Scholar 

  44. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol. 2006;44(1 Suppl):S65–70.

    Article  PubMed  Google Scholar 

  45. Mathews G, Bhagani S. The epidemiology and natural history of HIV/HBV and HCV co-infections. J HIV Ther. 2003;8:77–84.

    PubMed  Google Scholar 

  46. Stabinski L, Reynolds SJ, Ocama P, et al. High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther. 2011;16:405–11.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Ibrahim A, Shpaner A, Nieto J. Risk factors of accelerated liver fibrosis in HIV-HCV coinfection: a matched analysis. South Afr Gastroenterol Rev. 2004;2(3):14–7.

    Google Scholar 

  48. Mphahlele MJ. Impact of HIV co-infection on hepatitis B prevention and control: a view from Sub-Saharan Africa. South Afr J Epidemiol Infect. 2008;23(1):14–8.

    Google Scholar 

  49. Mayaphi SH, Roussow TM, Masemola DP, et al. HBV/HIV co-infection: the dynamics of HBV in South African patients with AIDS. South Afr Med J. 2012;102:157–62.

    Article  CAS  Google Scholar 

  50. Thio CL. Hepatitis B and human immunodeficiency virus co-infection. Hepatology. 2009;49(5 Suppl):S138–45.

    Article  PubMed  Google Scholar 

  51. Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut. 2012;61(Suppl 1):i47–58.

    Article  CAS  PubMed  Google Scholar 

  52. Andersson MI, Maponga TG, Ijaz S, et al. The epidemiology of hepatitis B virus infection in HIV-infected and HIV-uninfected pregnant women in the Western Cape, South Africa. Vaccine. 2013;31(47):5579–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Thio CL, Seaberg EC, Skolasky Jr R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360:1921–6.

    Article  PubMed  Google Scholar 

  54. Puoti M, Spinetti A, Ghezzi AJ, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr. 2000;24(3):211–7.

    Article  CAS  PubMed  Google Scholar 

  55. Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166(15):1632–41.

    Article  PubMed  Google Scholar 

  56. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005;19(6):593.

    Article  PubMed  Google Scholar 

  57. Kew MC. Hepatocellular carcinoma in African Blacks: recent progress in etiology and pathogenesis. World J Hepatol. 2010;2(2):65–73.

    PubMed  PubMed Central  Google Scholar 

  58. Sonderup MW, Wainwright H, Hall P, Hairwadzi H, Spearman CW. A clinicopathological cohort study of liver pathology in 301 patients with human immunodeficiency virus/acquired immune deficiency syndrome. Hepatology. 2015;61(5):1721–9.

    Article  CAS  PubMed  Google Scholar 

  59. Lok ASF, McMahon BJ. AASLD practice guidelines. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):1–65.

    Article  Google Scholar 

  60. WHO Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection 2015. www.who.int/mediacentre/news/releases/2015/hepatitis-b-guideline/en/. Accessed 4 Dec 2015.

  61. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–9.

    Article  CAS  PubMed  Google Scholar 

  62. WHO 2009 position paper on hepatitis B vaccines. Geneva: World Health Organization; No 40, 2009, 84, 405-420. http://www.who.int/wer.

  63. WHO/UNICEF Joint Reporting Form 2014, as at 05 November 2015 and ECDC published data at http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx

  64. WHO vaccine-preventable diseases: monitoring system. 2016 global summary. http://apps.who.int/immunization_monitoring/globalsummary

  65. Chen DS, Hsu NH, Sung JL, et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA. 1987;257(19):2597–603.

    Article  CAS  PubMed  Google Scholar 

  66. Hsu HM, Chen DS, Chuang CH, et al. Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen-carrier mothers. JAMA. 1988;260(15):2231.

    Article  CAS  PubMed  Google Scholar 

  67. Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA. 1996;276(11):906–8.

    Article  CAS  PubMed  Google Scholar 

  68. Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med. 2001;135(9):796–800.

    Article  CAS  PubMed  Google Scholar 

  69. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336:1855–9.

    Article  CAS  PubMed  Google Scholar 

  70. Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: a 20-year follow-up study. J Natl Cancer Inst. 2009;101(19):1348–55.

    Article  CAS  PubMed  Google Scholar 

  71. Chien YC, Jan CF, Chiang CJ, et al. Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: a 20-year cohort study of 3.8 million vaccines. Hepatology. 2014;60(1):125–32.

    Article  CAS  PubMed  Google Scholar 

  72. Kao JH. Hepatitis B vaccination and prevention of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2015;29(6):907–17.

    Article  PubMed  Google Scholar 

  73. Wiseman E, Fraser M, Holden S, Glass A, Kidson BL, Heron LG, et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust. 2009;190:489–92.

    PubMed  Google Scholar 

  74. Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat. 2012;19:e18–25.

    Article  CAS  PubMed  Google Scholar 

  75. Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology. 2014;60:468–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Pan CQ, Zou H-B, Chen Y, et al. Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants. Clin Gastroenterol Hepatol. 2013;11:1349–55.

    Article  PubMed  Google Scholar 

  77. del Canho R, Grosheide PM, Schalm SW, de Vries RR, Heijtink RA. Failure of neonatal hepatitis B vaccination: the role of HBV-DNA levels in hepatitis B carrier mothers and HLA antigens in neonates. J Hepatol. 1994;20:483–6.

    Article  PubMed  Google Scholar 

  78. Pan CQ, Han GR, Jiang HX, et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol. 2012;10:520–6.

    Article  CAS  PubMed  Google Scholar 

  79. Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A. 1991;88(6):2451–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Davis GL. Hepatitis C virus genotypes and quasispecies. Am J Med. 1999;107(6B):21S–6S.

    Article  CAS  PubMed  Google Scholar 

  81. Kamili S, Krawczynski K, McCaustland K, Li X, Alter MJ. Infectivity of hepatitis C virus in plasma after drying and storing at room temperature. Infect Control Hosp Epidemiol. 2007;28(5):519–24.

    Article  PubMed  Google Scholar 

  82. Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis. 2014;59(6):765–73.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58–68.

    Article  PubMed  Google Scholar 

  84. Resti M, Bortolotti F, Vajro P, et al. Guidelines for the screening and follow-up of infants born to anti-HCV positive mothers. Dig Liver Dis. 2003;35:453–7.

    Article  CAS  PubMed  Google Scholar 

  85. Resti M, Jara P, Hierro L, et al. Clinical features and progression of perinatally acquired hepatitis C virus infection. J Med Virol. 2003;70:373–7.

    Article  PubMed  Google Scholar 

  86. Yeung LT, To T, King SM, et al. Spontaneous clearance of childhood hepatitis C virus infection. J Viral Hepat. 2007;14:797–805.

    Article  CAS  PubMed  Google Scholar 

  87. European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis. 2005;41:45–51.

    Article  Google Scholar 

  88. Farmand S, Wirth S, Loffler H, et al. Spontaneous clearance of hepatitis C virus in vertically infected children. Eur J Pediatr. 2012;171:253–8.

    Article  PubMed  Google Scholar 

  89. Bortolotti F, Verucchi G, Camma C, et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology. 2008;134:1900–7.

    Article  PubMed  Google Scholar 

  90. Casiraghi MA, De PM, Romano L, et al. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology. 2004;39:90–6.

    Article  PubMed  Google Scholar 

  91. Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med. 1999;341:866–70.

    Article  CAS  PubMed  Google Scholar 

  92. Locasciulli A, Testa M, Pontisso P, et al. Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia. Blood. 1997;90:4628–33.

    CAS  PubMed  Google Scholar 

  93. Delgado-Borrego A, Healey D, Negre B, et al. Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection. J Pediatr Gastroenterol Nutr. 2010;51:191–7.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Cesaro S, Bortolotti F, Petris MG, et al. An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy. Pediatr Blood Cancer. 2010;55:108–12.

    PubMed  Google Scholar 

  95. Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis. 2009;200:1216–26.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Wise M, Finelli L, Sorvillo F. Prognostic factors associated with hepatitis C disease: a case-control study utilizing U.S. multiple-cause-of-death data. Public Health Rep. 2010;125:414–22.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Pastore M, Willems M, Cornu C, et al. Role of hepatitis C virus in chronic liver disease occurring after orthotopic liver transplantation. Arch Dis Child. 1995;72:403–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Zein CO, Levy C, Basu A, Zein NN. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol. 2005;100(1):48–55.

    Article  PubMed  Google Scholar 

  99. Granot E, Sokal EM. Hepatitis C virus in children: deferring treatment in expectation of direct-acting antiviral agents. Isr Med Assoc J. 2015;17(11):707–11.

    PubMed  Google Scholar 

  100. Wirth S, Pieper-Boustani H, Lang T, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology. 2005;41:1013–8.

    Article  CAS  PubMed  Google Scholar 

  101. Jara P, Hierro L, De la Vega A, et al. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J. 2008;27:142–8.

    PubMed  Google Scholar 

  102. Sokal EM, Bourgois A, Stephenne X, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol. 2010;52:827–31.

    Article  CAS  PubMed  Google Scholar 

  103. Balistreri WF, Murray KF, Rosenthal P. The safety and effectiveness of Ledipasvir-Sofosbuvir in adolescents 12 to 17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2016 December 20. [Epub ahead of print].

    Google Scholar 

  104. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378:73–85.

    Article  PubMed  Google Scholar 

  105. Buti M, Homs M, Rodriguez-Frias F, et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat. 2011;18:434–42.

    Article  CAS  PubMed  Google Scholar 

  106. Heller T, Rotman Y, Koh C, et al. Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther. 2014;40:93–104.

    Article  CAS  PubMed  Google Scholar 

  107. Rein DB, Stevens J, Theaker JS, Wittenborn ST, Wiersma ST. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology. 2012;55(4):988–97.

    Article  PubMed  Google Scholar 

  108. Dalton HR, Bendall R, Ijaz S, Banks M. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis. 2008;8:698–709.

    Article  PubMed  Google Scholar 

  109. Dalton HR, Pas SD, Madden RG, van der Eijk AA. Hepatitis E: current concepts and future perspectives. Curr Infect Dis Rep. 2014;16(4):399.

    Article  PubMed  Google Scholar 

  110. Teshale EH, Hu DJ. Hepatitis E: epidemiology and prevention. World J Hepatol. 2011;3(12):285–91.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Teshale EH, Hu DJ, Holmberg SD. The two faces of Hepatitis E. Clin Infect Dis. 2010;51:328–34.

    Article  PubMed  Google Scholar 

  112. Lu L, Li C, Hagedorn CH. Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis. Rev Med Virol. 2006;16:5–36.

    Article  CAS  PubMed  Google Scholar 

  113. Okamoto H. Genetic variability and evolution of hepatitis E virus. Virus Res. 2007;127:216–28.

    Article  CAS  PubMed  Google Scholar 

  114. Centers for Disease Control and Prevention 2008. http://www.cdc.gov/ncidod/diseases/hepatitis/slideset/hep_e/slide_1.htm. Accessed 8 Dec 2016.

  115. Teshale EH, Howard CM, et al. Hepatitis E epidemic, Uganda. Emerg Infect Dis. 2010;16:126–12.

    Article  PubMed  Google Scholar 

  116. Sharapov MB, Favorov MO, Yashina TL, et al. Acute viral hepatitis morbidity and mortality associated with hepatitis E virus infection: Uzbekistan surveillance data. BMC Infect Dis. 2009;9(35):1–9.

    Google Scholar 

  117. Khurro MS, Kamil S. Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy. J Viral Hepat. 2003;10:61–9.

    Google Scholar 

  118. Kumar A, Beniwal M, Kar P, Sharma JB, Murthy NS. Hepatitis E in pregnancy. Int J Gynaecol Obstet. 2004;85:240–4.

    Article  CAS  PubMed  Google Scholar 

  119. Mushahwar IK. Hepatitis E virus: molecular virology, clinical features, diagnosis, transmission, epidemiology, and prevention. J Med Virol. 2008;80(4):646–58.

    Article  PubMed  Google Scholar 

  120. Khurro MS, Rustgi VK, Dawson GJ, et al. Spectrum of hepatitis E virus infection in India. J Med Virol 1994;43:281–86.

    Google Scholar 

  121. Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008;358:811–7.

    Article  CAS  PubMed  Google Scholar 

  122. Kamar N, Garrouste C, Haagsma EB, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology. 2011;140:1481–9.

    Article  PubMed  Google Scholar 

  123. Haagsma EB, van den Berg AP, Porte RJ, Benne CA, Vennema H, Reimerink JH, Koopmans MP. Chronic hepatitis E virus infection in liver transplant recipients. Liver Transpl. 2008;14(4):547–53.

    Article  PubMed  Google Scholar 

  124. Dalton HR, Bendall R, Keane F, et al. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med. 2009;361:1025–7.

    Article  CAS  PubMed  Google Scholar 

  125. Ollier L, Tieulie N, Sanderson F, et al. Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab. Ann Intern Med. 2009;150:430–1.

    Article  PubMed  Google Scholar 

  126. Norvell JP, Blei AT, Jovanovic BD, Levitsky J. Herpes simplex virus hepatitis: an analysis of the published literature and institutional cases. Liver Transpl. 2007;13(10):1428–34.

    Article  PubMed  Google Scholar 

  127. Kimberlin DW, Lin CY, Jacobs RF, et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics. 2001;108(2):230–8.

    Article  CAS  PubMed  Google Scholar 

  128. Verma A, Dhawan A, Zuckerman M, Hadzic N, Baker AJ, Mieli-Vergani G. Neonatal herpes simplex virus infection presenting as acute liver failure: prevalent role of herpes simplex virus type I. J Pediatr Gastroenterol Nutr. 2006;42:282–6.

    Article  PubMed  Google Scholar 

  129. Egawa H, Inomata Y, Nakayama S, Matsui A, Yamabe H, Uemoto S, et al. Fulminant hepatic failure secondary to herpes simplex virus infection in a neonate: a case report of successful treatment with liver transplantation and perioperative acyclovir. Liver Transpl Surg. 1998;4:513.

    Article  CAS  PubMed  Google Scholar 

  130. Nakase H, Herfarth H. Cytomegalovirus colitis, cytomegalovirus hepatitis and systemic cytomegalovirus infection: common features and differences. Inflamm Intest Dis. 2016;1:15–23.

    Article  PubMed  PubMed Central  Google Scholar 

  131. Cohen JL. Epstein-Barr virus infection. N Eng J Med. 2000;343:481–92.

    Article  CAS  Google Scholar 

  132. Odumade OA, Hogquist KA, Balfour Jr HH. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin Microbiol Rev. 2011;24:193.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Yuge A, Kinoshita E, Moriuchi M, Ohno Y, Haga H, Moriuchi H. Persistent hepatitis associated with chronic active Epstein–Barr virus infection. Pediatr Infect Dis J. 2004;23:74–6.

    Article  PubMed  Google Scholar 

  134. Drebber U, Kasper HU, Krupacz J, et al. The role of Epstein–Barr virus in acute and chronic hepatitis. J Hepatol. 2006;44:879–85.

    Article  CAS  PubMed  Google Scholar 

  135. Feranchak AP, Tyson RW, Narkewicz MR, Karrer FM, Sokol RJ. Fulminant Epstein-Barr viral hepatitis: orthotopic liver transplantation and review of the literature. Liver Transpl Surg. 1998;4:469–76.

    Article  CAS  PubMed  Google Scholar 

  136. Torre D, Tambini R. Acyclovir for treatment of infectious mononucleosis: a meta-analysis. Scand J Infect Dis. 1999;31:543.

    Article  CAS  PubMed  Google Scholar 

  137. Rafailidis PI, Mavros MN, Kapaskelis A, Falagas ME. Antiviral treatment for severe EBV infections in apparently immunocompetent patients. J Clin Virol. 2010;49(3):151–7.

    Article  CAS  PubMed  Google Scholar 

  138. Cyran EM, Rowe JM, Bloom RE. Intravenous gammaglobulin treatment for immune thrombocytopenia associated with infectious mononucleosis. Am J Hematol. 1991;38(2):124–9.

    Article  CAS  PubMed  Google Scholar 

  139. Tebruegge M, Curtis N. Enterovirus infections in neonates. Semin Fetal Neonatal Med. 2009;14(4):222–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa

    C. Wendy Spearman

  2. Division of Paediatric Gastroenterology, Department of Paediatrics and Child Health, Faculty of Health Sciences, University of Cape Town and Red Cross War Memorial Children’s Hospital, Cape Town, South Africa

    Ronalda de Lacy & Elizabeth Goddard

Authors
  1. C. Wendy Spearman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronalda de Lacy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elizabeth Goddard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Wendy Spearman .

Editor information

Editors and Affiliations

  1. Department of Paediatrics and Child Health, University of Pretoria, School of Medicine, Pretoria, ZA, South Africa

    Robin J. Green

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Spearman, C.W., de Lacy, R., Goddard, E. (2017). Viral Hepatitis. In: Green, R. (eds) Viral Infections in Children, Volume II. Springer, Cham. https://doi.org/10.1007/978-3-319-54093-1_7

Download citation

Publish with us

Policies and ethics

Search

Navigation